Multiple Sclerosis – Roche BP46016

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.

Inclusion Criteria:

  • PMS, in accordance with the revised 2017 McDonald criteria
  • Expanded disability status scale (EDSS) at screening between 3.0 and 6.0 inclusive
  • Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.

 

View Study on ClinicalTrials.gov

Trial Interest Form

Locations

The Neurology Center of Southern California

6010 Hidden Valley Road
Suites 200 & 205
Carlsbad, California